Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 1;120(1):106-114.
doi: 10.14309/ajg.0000000000003092. Epub 2024 Sep 23.

Diagnosis and Management of Inflammatory Bowel Disease-Associated Spondyloarthritis

Katherine Falloon  1 , Michael Forney  2 , M Elaine Husni  3 , Brian Feagan  4   5 , Florian Rieder  1   6   7
Affiliations
Review

Diagnosis and Management of Inflammatory Bowel Disease-Associated Spondyloarthritis

Katherine Falloon et al. Am J Gastroenterol. .

Abstract

Inflammatory bowel disease (IBD)-associated spondyloarthritis (SpA) is common but remains poorly understood. In this review article, we aimed to provide guidance regarding the diagnosis and management of this condition. For diagnosis of IBD-associated peripheral SpA (IBD-pSpA), we recommend collaboration with rheumatology for incorporation of clinical symptoms, physical examination findings, joint imaging if applicable, and available diagnostic criteria. For the management of IBD-pSpA, we first recommend assessment and treatment of underlying luminal IBD disease activity. We provide guidance regarding positioning of advanced therapies for IBD in patients with IBD-pSpA based on the limited available literature. For diagnosis of IBD-associated axial SpA, we recommend rheumatology referral to make the diagnosis based on incorporation of symptoms, laboratory data, imaging findings (sacroiliitis), and available diagnostic criteria. For the management of axial SpA, we recommend comanagement with rheumatology and use of either antitumor necrosis factor agents or Janus kinase inhibitors, when applicable.

PubMed Disclaimer

References

    1. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011;106(1):110–9.
    1. Luchetti MM, Benfaremo D, Bendia E, et al. Clinical and patient reported outcomes of the multidisciplinary management in patients with inflammatory bowel disease-associated spondyloarthritis. Eur J Intern Med 2019;64:76–84.
    1. Falloon K, Dossaji Z, Mude P, et al. Diagnosis of inflammatory bowel diseases-associated peripheral spondyloarthritis: A systematic review. Inflamm Bowel Dis J. 2024. Online ahead of print.
    1. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: Their articular distribution and natural history. Gut 1998;42(3):387–91.
    1. Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 2016;10(3):239–54.

MeSH terms

Substances

LinkOut - more resources